Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma

We investigated the relationship between axitinib pharmacogenetics and clinical efficacy/adverse events in advanced renal cell carcinoma (RCC) and established a model to predict clinical efficacy and adverse events using pharmacokinetic and gene polymorphisms related to drug metabolism and efflux in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yoshiaki, Tsunedomi, Ryouichi, Fujita, Yusuke, Otori, Toru, Ohba, Mitsuyoshi, Kawai, Yoshihisa, Hirata, Hiroshi, Matsumoto, Hiroaki, Haginaka, Jun, Suzuki, Shigeo, Dahiya, Rajvir, Hamamoto, Yoshihiko, Matsuyama, Kenji, Hazama, Shoichi, Nagano, Hiroaki, Matsuyama, Hideyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908314/
https://www.ncbi.nlm.nih.gov/pubmed/29682213
http://dx.doi.org/10.18632/oncotarget.24715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908314/
https://www.ncbi.nlm.nih.gov/pubmed/29682213
http://dx.doi.org/10.18632/oncotarget.24715

Ejemplares similares